Considering the potential effectsof SGLT2 inhibition on arrythmias, two randomized clinical trials (NCT04792190and NCT04583813) aim to evaluate whether empagliflozin or dapagliflozin may beeffective to reduce atrial fibrillation burden, both in patients who undergocatheter ablation for atrial fibrillation (DAPA-AF [NCT04792190]) or patientswith diabetes mellitus or obesity with an indication for rhythm control (EMPA-AF[NCT04583813]). The gene discussed is SLC5A2; the disease is atrial fibrillation.